The Importance of HLA-DRB1 Alleles in Patients with Lupus Nephritis

Lupus Nefritli Hastalarda HLA-DRB1 Allellerinin Önemi

Atma GUNAWAN, Kusworini HANDONO, HandoNO KALIM, Hani SUSIANTI, Mudjiwijono Handaru EKO, Gatot S. LAWRENCE, Dian HASANAH, Etik MERTIANTI, Didi CANDRADIKUSUMA

Introduction: Our aim was to re-evaluate the roles of HLA-DRB1 alleles on susceptibility, severity, activity and chronicity index of lupus erythematosus nephritis in Indonesia.

Materials and Methods: A total of 55 lupus nephritis patients and 52 healthy subjects were analyzed. HLA-DRB1 alleles were examined by polymerase chain reaction (PCR) followed by electrophoresis. Differences in HLA-DRB1 allele frequencies between lupus nephritis group and healthy group were assessed using Chi-square test, presented as odds ratio (OR). Results were considered significant at P value less than 0.05.

Results: HLA-DRB1*1501 was a susceptible allele for lupus nephritis group (OR=3.18; p=0.010). HLA-DRB1*1501 was also a susceptible allele for high activity index (OR=7.4; p=0.006). Although not statistically significant, HLA-DRB1*1501 was a susceptible allele for high chronicity index (OR=3.2; p=0.07). We found HLA-DRB1*0401 was a protective allele against severe class of lupus nephritis (OR=9.4; p=0.029).

Conclusion: HLA-DRB1*1501 was a susceptible allele for lupus erythematosus nephritis with high activity and chronicity index. HLA-DRB1*0401 was a protective allele against severe class of lupus nephritis.

Keywords: Lupus erythematosus, lupus nephritis, HLA-DRB1, allele, activity, chronicity

Introduction

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. It may induce autoimmune nephritis (lupus nephritis). Several studies had shown that kidney involvement and severity of disease were genetically associated. HLA-DRB1 and HLA-DQ genes were known to predispose to SLE and lupus nephritis and were widely

Oz

Giris: Amacımız Endonezyada yaşayan lupus eritematosus olup nefriti sahip hastaların HLA-DRB1 allellerinin hastalığa olan etkisi, hastalığın ciddiyeti, etkinliği ve kronikliği üzerine etkisini incelemektir.

Gerçerler ve Yöntemler: Toplam 55 lupus nefriti olan hastalar ile 52 sağlıklı kişilik Controllers, polymeraz zincir tekipmesi yöntemi ve ardından elektroforez kullanılarak saptandı. Lupus nefriti olguları sağlıklı kişilere kıyaslandık. HLA-DRB1*1501 alleri yüksek kroniklik düzeyi olan olgulara ait frekansları, Hazan-Orman testi ile analiz edildi. P değeri 0.05 den büyük olması istatistiksel anlamlılık olarak kabul edildi.

Bulgular: HLA-DRB1*1501 alleri ile lupus nefriti hastalarının çapraz mortalitesi (Hazan-Orman=3.18; p=0.01). Aynı aller, aynı zamanda yüksek aktivite birimi ile de ilişkili olarak saptandı (Hazan-Orman=7.4; p=0.006). HLA1*1501 alleri, ne kadar istatistiksel olarak anlamalı düzeye olmasa da yüksek kroniklik düzeyi ile ilişkilidir (Hazan-Orman=3.2; p=0.07). Ayrıca HLA-DRB1*1401 alleri ile, hirs lupus nefritinin koruyucu olduğu saptandı (Hazan-Orman=9.4; p=0.029).

Sonuç: HLA-DRB1*1501, lupus eritematosus hastalarında nefritin etkinliğini ve kronikliğini ile ilişkilidir. HLA-DRB1*0401 ise, ciddi lupus nefritine karşı koruyucudur.

Anahtar Kelimeler: Lupus eritematosus, lupus nefriti, HLA-DRB1, allele, aktivite, kronisite
investigated.[1-3] Polymorphism of HLA-DRB1 were the most common. To date, there are 463 allelic variations of HLA-DRB1 gene. Research on the alleles of the HLA-DRB1 gene that affects the susceptibility and class of lupus nephritis resulted in different conclusions, depending on the population under study. In our study, we aimed to investigate the possible association of alleles of HLA-DRB1 gene with incidence, classes, activity and chronicity index of lupus nephritis.

Materials and Methods

Subjects

We analyzed the Javanese descendant patients who visited outpatient clinic and inpatient wards of Internal Medicine Department in Dr. Saiful Anwar General Hospital in Malang. Patients were diagnosed with nephritis caused by lupus erythematosus based on the American College of Rheumatology (ACR) 1997 criteria.[4] This study was approved by the Ethics Committee of Medical of the University of Universitas Brawijaya and Dr. Saiful Anwar General Hospital. All participants signed informed consent.

HLA-DRB1 examination

HLA-DRB1 alleles examination was performed using polymerase chain reaction (PCR) techniques with sequence specific primers (PCR-SSP method). Specific primers were designed to selectively amplify target sequences which were specific to a single or group of alleles. The presence of amplified DNA fragments indicated existence of specific allele sequences within DNA. Morgan HLA SSP DRB Typing kitTM with catalog number 33280 was used for determining this.

Identification of HLA-DRB1 gene polymorphism was done using 3 ml blood samples with EDTA through the steps of DNA isolation, PCR and electrophoresis. DNA isolation was performed using Qiagen kit and DNA concentration was expected between 10–40 ng/μl. Thermal cycler in PCR ran for approximately 1 hour 25 minutes. PCR products (12 μL) were continued to 2% agarose gel electrophoresis which separated DNA fragments by sizes. Amplified fragments were stained with ethidium bromide followed by ultraviolet light exposure. A worksheet was provided by manufacture to assist the determination of HLA types by analysing PCR results.

Statistic analysis

Normality and homogeneity was analysed with Kolmogorov-Smirnov and Levene test, respectively. Differences in HLA-DRB1 allele frequencies between lupus nephritis patients and healthy controls, between mild and severe classes and between high and low activity and chronicity index were analysed using Chi-square test and the relative risk was stated by odds ratio (OR). p value less than 0.05 was considered significant. The statistical analysis software used was SPSS 22(IBM Inc.; USA).

Results

In two years, 55 patients (94% of them were women) were diagnosed as lupus nephritis. All patients were on treatment. Based on ISN/RPS 2004 classification, there were 10 patients (18%) with class II lupus nephritis,[5] 24 patients (44%) with class III, 8 patients (14%) with class IV and 13 patients (23%) with mixed class V mixed. Severe classes consisted of class III, IV and mixed V; so there were 45 patients (82%) with severe classes and the other patients were the patients with class I and II disease. Classification of activity and chronicity index were based on National Institutes of Health (NIH) criteria.[6] Thirteen patients (24%) had high activity index. There were 29 patients (52.7%) patients with high chronicity index. Patients with severe classes experienced significantly more severe proteinuria than patients with Class I or II disease. (805.17±706.54 vs 99.52±92.6; p=0.001).

Table 1 shows that frequency of HLA-DRB1*1501 was significantly higher in lupus nephritis than that of control group (OR=3.18; p=0.010); whereas other HLA-DRB1 allele frequencies were not found to be different between two groups. Table 2 shows the differences in frequencies of HLA-DRB1 alleles among patients with mild and severe classes of lupus nephritis. HLA-DRB1*0401 were more common in mild classes (OR=9.4; p=0.029). Table 3 shows differences in frequencies of HLA-DRB1 alleles between the patients with low and high activity index lupus nephritis. HLA DRB1*1501 was more common in patients with high activity index group (OR=7.4; p=0.006). Table 4 shows that frequency of the HLA-DRB1*15 was higher in patients with high than that of in low chronicity index group, although the difference was not statistically significant (OR=3.2; p=0.07).
### Table 1. Distribution of HLA-DRB1 alleles in patients with lupus nephritis and control group. LN: Lupus nephritis, OR: Odds ratio. CI: Confidence interval.

| HLA-DRB1 alleles | LN (n=55) | Control (n=52) | p   | OR      | 95% CI       |
|------------------|-----------|----------------|-----|---------|--------------|
| DRB1*0401       | 3 (5.5%)  | 0 (0%)         | 0.090 | 5.526  | 0.27–112.93  |
| DRB1*0701       | 6 (10.9%) | 2 (3.8%)       | 0.180 | 2.778  | 0.54–14.4    |
| DRB1*0801       | 0 (0%)    | 1 (1.9%)       | 0.242 | 2.373  | 0.01–12.82   |
| DRB1*0820       | 0 (0%)    | 1 (1.9%)       | 0.242 | 2.373  | 0.01–12.82   |
| DRB1*0832       | 0 (0%)    | 2 (3.8%)       | 0.110 | 4.840  | 0.01–4.69    |
| DRB1*0901       | 2 (3.6%)  | 0 (0%)         | 0.161 | 3.621  | 0.16–82.11   |
| DRB1*1101       | 0 (0%)    | 2 (3.8%)       | 0.110 | 4.840  | 0.01–4.69    |
| DRB1*1105       | 0 (0%)    | 1 (1.9%)       | 0.242 | 2.373  | 0.01–12.82   |
| DRB1*1201       | 21 (38.2%)| 27 (51.9%)     | 0.063 | 2.006  | 0.23–1.07    |
| DRB1*1401       | 0 (0%)    | 0 (0%)         | 0.298 | 1.780  | 0.06–54.14   |
| DRB1*1404       | 0 (0%)    | 1 (1.9%)       | 0.242 | 2.373  | 0.01–12.82   |
| DRB1*1423       | 0 (0%)    | 1 (1.9%)       | 0.242 | 2.373  | 0.01–12.82   |
| DRB1*1446       | 0 (0%)    | 0 (0%)         | 0.161 | 3.621  | 0.16–82.11   |
| DRB1*1501       | 22 (40%)  | 8 (15.4%)      | 0.010 | 3.184  | 1.27–7.98    |
| DRB1*1517       | 1 (1.8%)  | 2 (3.8%)       | 0.397 | 2.360  | 0.04–4.81    |
| DRB1*1601       | 2 (3.6%)  | 4 (7.7%)       | 0.263 | 2.417  | 0.07–2.36    |

### Table 2. Distribution of HLA-DRB1 alleles in patients with mild and severe classes of lupus nephritis. OR: Odds ratio. CI: Confidence interval.

| HLA-DRB1 alleles | Mild (n=10) | Severe (n=45) | p     | OR     | 95% CI       |
|------------------|-------------|--------------|-------|--------|--------------|
| DRB1*0401       | 2 (20%)     | 1 (2.2%)     | 0.029 | 9.400  | 1.29–114.01  |
| DRB1*0701       | 1 (10%)     | 5 (11.1%)    | 0.669 | 1.279  | 0.08–7.39    |
| DRB1*0901       | 1 (10%)     | 1 (2.2%)     | 0.239 | 4.273  | 0.25–73.75   |
| DRB1*1201       | 3 (30%)     | 18 (40%)     | 0.359 | 1.800  | 0.13–2.32    |
| DRB1*1401       | 0 (0%)      | 1 (2.2%)     | 0.524 | 1.880  | 0.06–59.31   |
| DRB1*1446       | 0 (0%)      | 2 (4.4%)     | 0.406 | 1.087  | 0.04–21.72   |
| DRB1*1501       | 5 (50%)     | 17 (37.8%)   | 0.580 | 1.303  | 0.36–4.74    |
| DRB1*1517       | 0 (0%)      | 1 (2.2%)     | 0.524 | 1.880  | 0.06–59.31   |
| DRB1*1601       | 0 (0%)      | 2 (4.4%)     | 0.406 | 1.087  | 0.04–21.72   |

### Table 3. Distribution of HLA-DRB1 alleles in patients with low and high activity index lupus nephritis. OR: Odds ratio. CI: Confidence interval.

| HLA-DRB1 alleles | Low (n=34) | High (n=11) | p     | OR     | 95% CI       |
|------------------|------------|-------------|-------|--------|--------------|
| DRB1*0401       | 1 (2.9%)   | 0 (0%)      | 0.565 | 1.435  | 0.02–22.19   |
| DRB1*0701       | 4 (11.8%)  | 1 (9.1%)    | 0.806 | 1.333  | 0.13–13.37   |
| DRB1*0901       | 0 (0%)     | 1 (9.1%)    | 0.075 | 6.900  | 0.4–6.64     |
| DRB1*1201       | 16 (47.1%) | 2 (18.2%)   | 0.089 | 4.000  | 0.75–21.33   |
| DRB1*1401       | 0 (0%)     | 1 (9.1%)    | 0.075 | 6.900  | 0.4–6.64     |
| DRB1*1446       | 1 (2.9%)   | 1 (9.1%)    | 0.390 | 3.300  | 0.02–5.29    |
| DRB1*1501       | 9 (26.5%)  | 8 (72.7%)   | 0.006 | 7.407  | 1.6–34.21    |
| DRB1*1517       | 1 (2.9%)   | 0 (0%)      | 0.565 | 1.435  | 0.02–22.19   |
| DRB1*1601       | 2 (5.9%)   | 0 (0%)      | 0.411 | 1.438  | 0.06–34.27   |
Table 4. Distribution of HLA-DRB1 alleles in patients with low and high chronicity index lupus nephritis. OR: Odds ratio. CI: Confidence interval.

| HLA-DRB1 alleles | Chronicity index n (%) | p     | OR   | 95% CI     |
|------------------|------------------------|-------|------|------------|
|                  | Low (n=21)             | High (n=24) |
| DRB1*0401        | 1 (4.8%)                | 0 (0%) | 0.280 | 2.450      | 1.08–76.85 |
| DRB1*0701        | 1 (4.8%)                | 4 (16.7%) | 0.205 | 4.000      | 1.03–5.44  |
| DRB1*0901        | 0 (0%)                  | 1 (4.2%) | 0.344 | 1.870      | 1.02–16.77 |
| DRB1*1201        | 8 (38.1%)               | 10 (41.7%) | 0.807 | 1.161      | 0.26–2.85  |
| DRB1*1401        | 0 (0%)                  | 1 (4.2%) | 0.344 | 1.870      | 1.02–16.77 |
| DRB1*1446        | 1 (4.8%)                | 1 (4.2%) | 0.923 | 1.150      | 0.07–19.6  |
| DRB1*1501        | 5 (23.8%)               | 12 (50%) | 0.071 | 3.200      | 1.09–8.13  |
| DRB1*1517        | 0 (0%)                  | 1 (4.2%) | 0.344 | 1.870      | 1.02–16.77 |
| DRB1*1601        | 0 (0%)                  | 2 (8.3%) | 0.176 | 3.909      | 1.01–6.1   |

Discussion

HLA-DRB1 gene which is a risk factor for lupus nephritis has different alleles. [1] Bastian’s study that was conducted in multi-ethnic population in The United States of America showed that HLA-DRB1*1503 was a risk factor for lupus nephritis. [2] In contrast, HLA-DR3 and HLA-DQB1*0201 were found to be protective against lupus nephritis. [2] A study that was performed in 155 children and adolescent SLE in Brazil also reported that HLA-DRB1*15 was a risk allele for lupus nephritis. [7] It was also documented that HLA-DRB1*15 was associated with elevated levels of anti-dsDNA, anti- Sm, anti-U1-RNP and anti-SSA/Ro antibodies. [7] In Italy, it was found that HLA-DQA1*0101 and HLA-DRB1*1501 were risk alleles for lupus nephritis. [1] The article published by Walid (2014) in Saudi Arabia also indicated that HLA-DRB1*15 was associated with lupus nephritis. [8]

A Taiwanese study stated that no alleles of HLA-DRB1 gene were risk factors for lupus nephritis. [9] On the other hand a study from Malaysia emphasized that alleles as risk factor for lupus nephritis were HLA-DR, HLA-DQB1*0501. [7] Whereas, in a Korean study, risk allele for lupus nephritis was reported to be HLA-DRB1*07. [8] Another study from Hungary stated that HLA-DR3 and HLA-DR7 were risk alleles for lupus nephritis. [9]

Our study showed that HLA-DRB1*1501 was a risk allele for lupus nephritis (OR=3.18; p=0.010). But unlike other studies, there was no protective allele described against lupus nephritis in our study. HLA-DRB1*1202 was reported to be protective against lupus nephritis in Taiwanese population. [9] In a study performed in The United States of America indicated that, protective alleles against lupus nephritis were HLA-DR3 and HLA-DQB1*0201.

Our results showed that HLA-DRB1*1501 allele was not only a risk allele for lupus nephritis, but also a risk factor for development of lupus nephritis with high activity and high chronicity index. These results were similar to sthose published An Italian study stated that 80% of patients with HLA-DRB1*15 fell into severe classes of diffuse proliferative (class IV), the remaining 20% into focal proliferative (class III). [1] On the other hand in Brazilian patients, HLA-DRB1*15 and HLA-DRB1*07 were significantly associated with class IIB and V disease. [4] HLA-DR3 was found to be a risk factor for development of class III, IV and V disease in Egyptian population. Pan et al. did not find a specific allele of HLA-DRB1 that affected the severity of lupus nephritis. [9]

Yung et al. (2006) showed that cultured human mesangial and tubular epithelium cells, induced with anti-DNA antibodies, produced pro-inflammatory cytokines, IL-1β, IL-6, TNF-α, TGF-β1 and matrix protein accumulation, fibronectin, in mesangial cells. [10]

Another possible risk factor associated with HLA-DRB1*1501 is related to the amino acid sequence. [11] HLA-DRB1 has a specific amino acid sequence which is able to present the antigen. [11] Kim et al. (2014) conducted the first mapping study in Korea to find relationship between SLE with HLA-DRB1 at the amino acid level. [11] Arg13 and Tyr13 were found to be associated with SLE, while His13 and Ser13 were found to be negatively correlated with the disease. There were two HLA-DRB1 alleles that were risk
for SLE: HLA-DRB1*1501 (containing Arg13) and HLA-DRB1*0301 (containing Tyr26). These amino acids were risk factors because they were hydrophobic and were located in the epitope-binding groove area. Hydrophobic residues made the protein easy to fold, formed a unique three-dimensional structure and they are especially necessary for biological activity, the ability to present antigens.

We were also able to find that HLA-DRB1*0401 was protective against severe nephritis. Another study by Jacob et al. also indicated that DR4 (HLA-DRB1*0401) was protective against lupus nephritis. Protective properties of HLA-DRB1*0401 might be attributable to TNF-α secreting effect. TNF-α inhibits viruses and parasites and has anti-tumour activity. Presumably, high levels of TNF-α was associated with protective effect on lupus nephritis.

We conclude that HLA-DRB1*1501 was associated with higher probability of lupus nephritis with high activity and high chronicity index. HLA-DRB1*0401 seems to be protective against development of severe lupus nephritis.

References

1. Marchini M, Antonioli R, Lleo A, Barili M, Caronni M, Origi L, et al. HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol 2003;64:462–8. [CrossRef]
2. Bastian HM, Alarcón GS, Roseman JM, McGwin G, Vila LM, Fessler BJ, et al. Systemic lupus erythematosus in a multiracial US cohort (LUMINA) XI. II. factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 2007;46:683–9. [CrossRef]
3. Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, et al. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology 2013;52:1172–82. [CrossRef]
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.
5. Markowitz GS1, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007 Mar;71(6):491-5. Epub 2007 Jan 31.
6. M. Bajema, Ingeborg & Wilhelmus, Suzanne & Alpers, Charles & A. Bruijn, Jan & Colvin, Robert & Terence Cook, H & D. D’Agati, Vivette & Ferrari, Franco & Haas, Mark & Charles Jennette, J & Joh, Kensuke & Nast, Cynthia & Joel, Laure-Hélène & Rijnink, Emilie & S.D. Roberts, Ian & Seshan, Surya & Sethi, Sanjeev & Fogo, Agnes. (2018). Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International. 93. 10.1016/j.kint.2017.11.023.
7. Liphhaus BL, Kiss MHB, Goldberg AC. HLA-DRB1 alleles in juvenile-on set systemic lupus erythematosus: renal histologic class correlations. Braz J Med Biol Res 2007;40:591–7. [CrossRef]
8. Wadi W, Elhefny Noor eldeen AM, Mahgoub EH, Almogren A, Hamam KD, Al-hamed HA, Gasim GI. Relation between HLA typing and clinical presentations in Systemic Lupus Erythematosus patients in Al-Qassim region, Saudi Arabia. Int J Health Sci 2014;8:159–65. [CrossRef]
9. Pan CF, Wu CJ, Chen HH, Dang CW, Chang FM, Liu HF, et al. Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematosus and lupus nephritis in Taiwan. Lupus 2009;18:698–704. [CrossRef]
10. Hwa CC, Maude EP, Kek HC. Genetic risk factors of systemic lupus erythematosus in the Malaysian population: a mini review. Clin Dev Immunol, 2012;2012. [CrossRef]
11. Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, et al. Independent association of HLA-DR and FCγ receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatology 2003;42:1501–7. [CrossRef]
12. Endreffy E, Kovacs A, Kovacs L, Pokorny G. HLA class II allele polymorphism in Hungarian patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1017–8. [CrossRef]
13. Yung S, Tsang RCW, Leung JKH, Chan TM. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1β. Kidney Int 2006;69:272–80. [CrossRef]
14. Kim K, Bang SY, Lee HS, Okada Y, Han B, Saw WY, et al. The HLA-DR beta-1 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nat Commun 2014;5:5902. [CrossRef]
15. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumour necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990;87:1233–7. [CrossRef]